[1] World Health Organization. Global tuberculosis report 2020 [R/OL]. Geneva, Switzerland: WHO, 2020. https://www.who.int/
publications/i/item/9789240013131.
[2] RIVERS E C, MANCERA R L. New anti-tuberculosis drugs with novel mechanisms of action [J]. Curr Med Chem, 2008, 15(19):
1956-1967.
[3] FRIEDEN T R, STERLING T, PABLOS-MENDEZ A, et al. The emergence of drug-resistant tuberculosis in New York City [J]. N
Engl J Med, 1993, 328(8): 521-526.
[4] ALEXANDER P E, DE P. The emergence of extensively drug-resistant tuberculosis (TB): TB/HIV coinfection, multidrug-esistant
TB and the resulting public health threat from extensively drug-resistant TB, globally and in Canada [J]. Can J Infect Dis Med Microbiol, 2007, 18(5): 289-291.
[5] VELAYATI A A, MASJEDI M R, FARNIA P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super
extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran [J]. Chest, 2009, 136(2): 420-425.
[6] WRIGHT C C, HSU F F, ARNETT E, et al. The Mycobacterium tuberculosis MmpL11 cell wall lipid transporter is important
for biofilm formation, intracellular growth, and nonreplicating persistence [J]. Infect Immun, 2017, 85(8). DOI: 10.1128/
IAI.00131-17.
[7] ABRAHAMS K A, BESRA G S. Mycobacterial cell wall biosynthesis: a multifaceted antibiotic target [J]. Parasitology, 2018, 145(2): 116-133.
[8] BROWN L, WOLF J M, PRADOS-ROSALES R, et al. Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi [J]. Nat Rev Microbiol, 2015, 13(10): 620-630.
[9] JANKUTE M, COX J A G, HARRISON J, et al. Assembly of the mycobacterial cell wall [J]. Annu Rev Microbiol, 2015, 69: 405-
423.
[10] BHAT Z S, RATHER M A, MAQBOOL M, et al. Cell wall: A versatile fountain of drug targets in Mycobacterium tuberculosi s [J].
Biomed Pharmacother, 2017, 95: 1520-1534.
[11] GRZEGORZEWICZ A E, PHAM H, GUNDI V A K B, et al. Inhibition of mycolic acid transport across the Mycobacterium
tuberculosis plasma membrane [J]. Nat Chem Biol, 2012, 8(4): 334-341.
[12] DOMENECH P, REED M B, BARRY C E. Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and
drug resistance [J]. Infect Immun, 2005, 73(6): 3492-3501.
[13] VILJOEN A, DUBOIS V, GIRARD-MISGUICH F, et al. The diverse family of MmpL transporters in mycobacteria: from regulation to antimicrobial developments [J]. Mol Microbiol, 2017, 104(6): 889-904.
[14] SACKSTEDER K A, PROTOPOPOVA M, BARRY C, et al. Discovery and development of SQ109: a new antitubercular drug
with a novel mechanism of action [J]. Future Microbiol, 2012, 7(7): 823-837.
[15] ZHANG B, LI J, YANG X, et al. Crystal structures of membrane transporter MmpL3, an anti-TB drug target [J]. Cell, 2019, 176(3): 636-648. e13.
[16] TSUKAZAKI T, MORI H, ECHIZEN Y, et al. Structure and function of a membrane component SecDF that enhances protein
export [J]. Nature, 2011, 474(7350): 235-238.
[17] MURAKAMI S, NAKASHIMA R, YAMASHITA E, et al. Crystal structures of a multidrug transporter reveal a functionally rotating
mechanism [J]. Nature, 2006, 443(7108): 173-179.
[18] EICHER T, SEEGER M A, ANSELMI C, et al. Coupling of remote alternating-access transport mechanisms for protons and substrates in the multidrug efflux pump AcrB [J]. Elife, 2014, 3: e03145. DOI: 10.7554/eLife.03145
[19] RINALDI-CARMONA M, BARTH F, HEAULME M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor [J]. FEBS Lett, 1994, 350(2/3): 240-244.
[20] ESCUYER V E, LETY M-A, TORRELLES J B, et al. The role of the embA and embB gene products in the biosynthesis of the
terminal hexaarabinofuranosyl motif of Mycobacterium smegmatis arabinogalactan [J]. J Biol Chem, 2001, 276(52): 48854-48862.
[21] ZHANG N, TORRELLES J B, MCNEIL M R, et al. The Emb proteins of mycobacteria direct arabinosylation of lipoarabinomannan and arabinogalactan via an N-terminal recognition region and a C-terminal synthetic region [J]. Mol Microbiol, 2003, 50(1): 69-76.
[22] GOUDE R, AMIN A G, CHATTERJEE D, et al. The critical role of embC in Mycobacterium tuberculosis [J]. J Bacteriol, 2008,
190(12): 4335-4341.
[23] SAFI H, SAYERS B, HAZBON M H, et al. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin [J]. Antimicrob Agents Chemother, 2008, 52(6): 2027-2034.
[24] SUN Q, XIAO T-Y, LIU H-C, et al. Mutations within embCAB are associated with variable level of ethambutol resistance in
Mycobacterium tuberculosis isolates from China [J]. Antimicrob Agents Chemother, 2018, 62(1): e01279-17.
[25] ZHAO L, SUN Q, LIU H, et al. Analysis of embCAB mutations associated with ethambutol resistance in multidrug-resistant
Mycobacterium tuberculosis isolates from China [J]. Antimicrob Agents Chemother, 2015, 59(4): 2045-2050.
[26] BROSSIER F, SOUGAKOFF W, BERNARD C, et al. Molecularanalysis of the embCAB locus and e mbR gene involved in
ethambutol resistance in clinical isolates of Mycobacterium tuberculosis in France [J]. Antimicrob Agents Chemother, 2015,
59(8): 4800-4808.
[27] ZHANG L, ZHAO Y, GAO Y, et al. Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol
[J]. Science, 2020, 368(6496): 1211-1219.
[28] BORASTON A B, BOLAM D N, GILBERT H J, et al. Carbohydrate-binding modules: fine-tuning polysaccharide recognition [J]. Biochem J, 2004, 382(Pt 3): 769-781.
[29] PLINKE C, COX H S, ZARKUA N, et al. embCAB sequence variation among ethambutol-resistant Mycobacterium tuberculosis
isolates without embB 306 mutation [J]. J Antimicrob Chemother, 2010, 65(7): 1359-1367.
[30] COLE S T, BROSCH R, PARKHILL J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome
sequence [J]. Nature, 1998, 393(6685): 537-544.
[31] MEGEHEE J A, HOSLER J P, LUNDRIGAN M D. Evidence for a cytochrome bcc-aa3 interaction in the respiratory chain of
Mycobacterium smegmatis [J]. Microbiology (Reading), 2006, 152(Pt 3): 823-829.
[32] KAO W-C, KLEINSCHROTH T, NITSCHKE W, et al. The obligate respiratory supercomplex from Actinobacteria [J]. Biochim Biophys Acta, 2016, 1857(10): 1705-1714.
[33] PETHE K, BIFANI P, JANG J, et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis [J]. Nat Med, 2013, 19(9): 1157-1160.
[34] GONG H, LI J, XU A, et al. An electron transfer path connects subunits of a mycobacterial respiratory supercomplex [J]. Science, 2018, 362(6418): eaat8923. DOI: 10.1126/science.aat8923.
|
